# Curve Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curve-biosciences

- Industry: Biotechnology
- Headquarters: Dallas, US
- Website: www.curvebio.com
- Total disclosed funding: $21M
- Latest round: Series A (May 1, 2024)
- Investors on record: 5

## About

Based in California, US, and founded in 2021, Curve Biosciences, Inc. operates as a biotechnology company that focuses on developing precision medicine that targets the biological changes in tissues that result in the development and progression of chronic diseases. In May 2024, Curve Biosciences, Inc. raised USD 17.69 million in venture funding. As of May 2024, the company is led by Nathan Hunkapiller (CSO) and Chuba Oyolu (CTO). In October 2025, Curve Biosciences, Inc. raised USD 40 million in venture funding led by new investor Luma Group, with participation from other new investors Civilization Ventures, First Spark Ventures, Incite Ventures, LifeX Ventures, Mintaka, and NZVC. Individual and other unspecified investors also participated in the round. The company will use the funding to develop its health platform, prepare it for clinical use, and begin offering blood tests.

The company leverages a chronic disease tissue atlas and a data-driven approach to discover and develop precision medicine solutions that target chronic illnesses such as liver disease, endometriosis, and inflammatory bowel disease.

## Funding rounds

- Series A, May 1, 2024, $18M — Epidarex Capital, Pfizer Venture Investments, Advent Life Sciences, Columbus Venture Partners, British Patient Capital
- Seed, Jul 31, 2020, $3M — Epidarex Capital, Advent Life Sciences

## Investors

- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Seed, Series A
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Seed, Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- Columbus Venture Partners (https://capitalatlas.ai/funds/columbus-venture-partners) — Series A
- British Patient Capital — Series A